Singapore markets open in 2 hours 15 minutes
  • Straits Times Index

    3,041.29
    -79.29 (-2.54%)
     
  • S&P 500

    4,567.00
    -88.27 (-1.90%)
     
  • Dow

    34,483.72
    -652.22 (-1.86%)
     
  • Nasdaq

    15,537.69
    -245.14 (-1.55%)
     
  • BTC-USD

    57,268.77
    -911.17 (-1.57%)
     
  • CMC Crypto 200

    1,456.40
    +13.62 (+0.94%)
     
  • FTSE 100

    7,059.45
    -50.50 (-0.71%)
     
  • Gold

    1,773.30
    -9.00 (-0.50%)
     
  • Crude Oil

    67.00
    -2.95 (-4.22%)
     
  • 10-Yr Bond

    1.4430
    -0.0870 (-5.69%)
     
  • Nikkei

    27,821.76
    -462.16 (-1.63%)
     
  • Hang Seng

    23,475.26
    -376.98 (-1.58%)
     
  • FTSE Bursa Malaysia

    1,513.98
    +3.41 (+0.23%)
     
  • Jakarta Composite Index

    6,533.93
    -74.36 (-1.13%)
     
  • PSE Index

    7,200.88
    -77.56 (-1.07%)
     

Bharat Biotech's Covaxin for Children Aged 2-18 Likely to be Rolled-out in Phases: Report

·1-min read

With India planning a phased roll-out of the Covid-19 vaccine for children, the approval for Bharat Biotech’s Covaxin for use in the 2-18 years age group may take time before it is made available for people.

The Drugs Controller General of India (DCGI) is carefully examining the recommendation by the expert panel and evaluating several factors, Business Standard reported on Wednesday.

The panel had recommended the usage of Covaxin for children as young as two last week. The final approval for 2-18 years old is under expert opinion and evaluation.

The DCGI will hold discussions with the health minister, PMO, and Bharat Biotech before granting EUA to Covaxin, sources added.

On October 5, an expert panel of the Central Drugs Standard Control Organisation (CDSCO) recommended granting emergency use authorization (EUA) for Bharat Biotech manufactured Covaxin for those aged 2 to 18. Reportedly, a Drugs Controller General of India (DCGI) official has confirmed the development, adding final approval is still awaited.

Read all the Latest News, Breaking News and Coronavirus News here. Follow us on Facebook, Twitter and Telegram.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting